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ABSTRACT 
 
Objectives  
To evaluate and determine the value of monitoring models developed by the Mahidol 
Oxford Tropical Research Unit and the East African Consortium for Clinical Research, 
consider how this value can be measured and explore monitors and investigators 
experiences of and views about the nature, purpose and practice of monitoring.  
 
Research Design  
The monitoring model case studies represent interventions aimed at changing practice 
hence a participatory action research methodology was applied and 34 interviews, 5 focus 
groups and observations of monitoring activities conducted.  
 
Setting and Participants 
Fieldwork occurred in the places where the monitoring models are coordinated and applied 
in Thailand, Cambodia, Uganda and Kenya. Participants included those coordinating the 
monitoring schemes, monitors, senior investigators and research staff.   
 
Analysis 
Transcribed textual data from field notes, interviews and focus groups was imported into a 
qualitative data software programme (NVIVO 10) and analysed inductively and thematically 
by a qualitative researcher. The initial coding framework was reviewed internally and two 
main categories emerged from the subsequent interrogation of the data.  
 
Results  
These categories identified related to the conceptual framing and nature of monitoring, and 
the practice of monitoring, including relational factors. Particular emphasis was give to the 
value of a scientific and cooperative style of monitoring as a means of enhancing data 
quality, trust and transparency. In terms of practice the primary purpose of monitoring was 
defines as improving the conduct or health research and increasing the capacity of 
researchers and trial sites.  
 
Conclusions 
The models studied utilize internal and network wide expertise to improve the ethics and 
quality of clinical research. They demonstrate how monitoring can be a scientific and 
constructive exercise rather than threatening process. The value of cooperative relations 
needs to given more emphasis in monitoring activities, which seek to ensure that research 
protects human rights and produces reliable data.  
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ARTICLE SUMMARY 
 
Article Focus 
• Escalating bureaucracy and regulatory burden is increasing the costs of conducting 
trials, and deterring researchers from conducting high quality science 
• There is significant interest in innovative monitoring models which distil the essence 
of regulatory guidelines in a workable and scientific manner  
• We evaluated two models developed in international health settings to document 
their implementation, describe the challenges encountered and the good practices 
developed, and increase our understanding of the purpose of monitoring.   
Key Messages 
• More emphasis needs to be placed on the cooperative nature of monitoring and the 
need for monitoring practice to have a clear scientific focus 
• The primary purpose of on-site monitoring is to improve the conduct of health 
research and increase the capacity of researchers and trial sites, and the success of 
monitoring should be measured by corrective action rather than by identification of 
faults 
• There is a need for mixed methods research to evaluate a combined approach of 
cooperative and scientifically guided on-site monitoring and central statistical 
monitoring 
Strengths and Limitations 
• Addresses a gap in the literature on on-site monitoring in low-income and middle 
income settings 
• Lack of focus on and access to quantitative data which could be collated from 
monitoring reports and plans, and budgetary documents outlining trials costs 
• Unable to compare the monitoring reports of studies monitored by our case studies 
and other sponsor delegated monitoring groups. 
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BACKGROUND  
 
In the field of health research the practice of monitoring has become associated with 
compliance with the  ‘International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use’-Good Clinical Practice 
Guidelines’ (ICH-GCP), and related Federal (United States) and European trial regulations [1-
4]. In ICH-GCP sponsors are delegated responsibility for quality management of which 
monitoring is an integral component. Monitoring is defined as: ‘The act of overseeing the 
progress of a clinical trial, and of ensuring that it is conducted, recorded, and reported in 
accordance with the protocol, Standard Operating Procedures (SOPs), Good Clinical Practice 
(GCP), and the applicable regulatory requirements’ [1]. Section 5.18 of ICH-GCP emphasises 
that the main purpose of monitoring is to verify that the rights and well being of human 
participants are protected. Whilst this overarching ethical purpose is reflected in the 
detailed ICH-GCP guidance, the intrinsic emphasis on record keeping can serve to obscure 
this primary purpose.  
 
Escalating bureaucracy and regulatory burden is increasing the costs of conducting trials, 
and deterring researchers from conducting high quality science [5-7]. Whilst the role of ICH-
GCP in improving quality is widely acknowledged there are questions about its’ application 
in health research, specifically in trials not involving investigational medicinal products [8].  
It is argued that the well-intended values and principles of ICH-GCP have become hampered 
by bureaucracy and misapplication [9 ,10]. An associated ‘tick box’ standard is considered to 
divert attention away from key questions about the ethical process, study endpoints and 
data validity. Delegating monitoring activities to ‘contract research organisations’ (CROs) 
can extenuate this bureaucracy and lead to the misconception that ICH-GCP is highly 
complex and only achievable with huge resources [9]. This can be particularly detrimental to 
research undertaken in low and middle income countries where competitive market forces 
have resulted in clinical research becoming more driven by profit than local health needs 
[11].    
 
ICH-GCP requires that trials should be monitored according to the complexity and nature of 
the trial. The European Medicines Agency and the Food and Drugs Administration have 
released new guidance documents, which encourage sponsors to apply a risk and 
complexity assessment to trials. The aim is to reduce logistical and financial burdens of 
conducting 100% data validation [12 ,13]. This approach was endorsed at the Toronto 
‘Sensible Guidelines Meeting’ in May 2012 [14].  Increasing attention is therefore being paid 
to rationalising monitoring activities to reflect the risks posed to participants, and to ensure 
trials generate accurate data to support decision-making about the safety, efficacy or 
effectiveness of new products and health interventions [15].  
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Central statistical monitoring (CSM), applied remotely through advanced statistical and 
bioinformatics methods, is proposed as a way of achieving the latter, particularly in multi-
site trials [16 ,17]. Baigent et al cite the following taxonomy of errors affecting trials 1) 
Design Error/Procedural Error 2) Recording Error 3) Fraud, and 4) Analytical Error [17] . They 
argue that on-site monitoring should target errors, requiring due attention at specific trial 
sites. Hence CSM is not a stand-alone solution but needs to be complemented by proactive 
on-site monitoring. Experience shows that proactive on-site monitoring (e.g. peer-review) 
can enhance the quality of data and trial processes (e.g. participant consent) [18 ,19].  
 
Diverse opinion exists amongst investigators, sponsors and regulators about the definition 
and organisation of monitoring. Points of debate are the balance between CSM and on-site 
monitoring, the difference between audit and monitoring, and who should undertake these 
activities. Be it external CROs, in-house pharmaceutical monitors, or quality management 
teams embedded at trial sites. In this discussion there is a dearth of literature from 
international settings. Macefield et al’s recent systematic review of on-site monitoring 
methods for health care randomised controlled trials was only able to include 7 multi-
national articles[20]. They concluded that there was a paucity of evidence and a need for 
further evaluation trials.  
 
In our research we evaluated 2 innovative monitoring models, which are being implemented 
by Mahidol Oxford Tropical Medicine Research Unit in Thailand (MORU) and by the East 
African Consortium for Clinical Research (EACCR).  Our aims were to determine the value of 
these models, consider how this could be measured and explore monitors and investigators 
experiences of and views about the nature, purpose and practice of monitoring.  
 
 
METHODS  
 
Research Design  
 
We used a case study approach to evaluate the MORU and EACCR monitoring models in 
their real life contexts [21]. The case studies represent interventions which aim to change 
and improve practice therefore we applied a participatory methodological approach akin to 
action research [22]. Our research team included representatives from the case studies who 
could act on interim findings during the course of the research. A qualitative researcher 
(QR), who did not occupy an active or a collaborative role in the monitoring case studies, 
coordinated the study. The QR spent two weeks with members of each monitoring case 
study, during these fieldwork visits she observed monitoring activities, participated in a 
training workshop, reviewed documentary sources, and interviewed investigators and 
monitors associated with the case studies.  
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Study Participants 
 
The sample was drawn purposively in order to select ‘information rich’ representatives from 
two groups: 1) Those actively involved in the development, coordination and 
implementation of the monitoring case studies, and 2) Investigators and research staff 
whose work is being monitored by the monitoring case studies.  The first group includes 
monitors and key informants (KIs) some of who are senior researchers within the MORU and 
EACCR networks. Potential participants were informed about the purpose of the study and 
related research activities verbally and provided with study information sheet in advance of 
the researcher’s fieldwork visits. At MORU the QR also presented an overview of the study 
at the central MORU offices. The QR obtained informed consent from monitors and 
investigators who were willing to be interviewed and agreed to her observing their research 
and monitoring activities.  
 
A total of 56 participants were recruited (Group 1=35, Group 2=21) participants from the 
case studies, 26 from MORU and 30 from EACCR.  Group 1 comprises 9 key informants  
(MORU=5, EACCR= 4) and 26 (MORU=6, EACCR=20) monitors. In the EACCR case study all of 
the monitors were also active researchers. Key informants were senior investigators and 
those with experience of quality management, who had played a significant role in the 
development of the respective monitoring schemes. Group 2 comprises different cadres of 
staff: senior investigators (MORU=2), site investigators/trial coordinators (MORU=4, 
EACCR=3) and trial staff (MORU=9, EACCR=3) including some who were specifically 
responsible for quality control. Table 1 provides details of participants’ demographic 
characteristics. Of note is that the sample includes highly experienced and qualified 
international research professionals.  
 
Fieldwork  
 
In April 2012 the QR visited the MORU offices and research facilities in Bangkok and 
associated research centres/clinics on the Thai-Burmese border (Shoklo Medical Research 
Unit) and at Pailin District Hospital, Cambodia. All of these research facilities were involved 
in an antimalarial resistance trial and the researcher was able to observe monitoring 
activities at each facility. Interviews were held with 8 trial investigators, 5 KIs and 6 
monitors. Two group interviews with members of trial staff based at Thai-Burmese border 
clinics were conducted, one with two participants and the other with 5.  Thai and Karen 
translators helped facilitate the group interviews and 2 individual interviews with Thai 
researchers.   
 
In May 2012 the QR travelled to sites connected with the EACCR monitoring case study and 
observed a workshop for EACCR monitors. In Uganda she visited the Ugandan Virus 
Research Institute, the International AIDS Vaccine Initiative and Medical Research Council 
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offices in Entebbe and observed a two-day monitoring visit of an observational HIV 
treatment trial at Masaka Referral Hospital. In Kenya she accompanied two monitors on a 
three day monitoring visit of an HIV prevention trial for sero-discordant couples. During the 
EACCR fieldwork 6 investigators, 4 KIs and 6 monitors were interviewed. Three group 
interviews were conducted with 15 (4, 5, 6) monitors during a two day monitors training and 
feedback workshop held in Nairobi in May 2012. This workshop provided rich insights into 
the challenges and successes experienced by EACCR monitors. 
 
Across both case studies 34 individual interviews were conducted with 12 investigators, 9 
key informants and 13 monitors, and 2 focus groups with investigators and 3 with monitors.  
The interviews covered a wide range of topics including the history, purpose and value of 
the monitoring models, experiences gained and practical and ethical challenges 
encountered during their implementation and, the definition of monitoring and how to 
measure or evaluate good practice.  
 
Analysis 
 
Data constituted of field notes, interview and focus groups recordings and transcripts, 
monitoring reports and other documents relating to the case studies. Recordings were 
transcribed verbatim with the exception of oral contributions in Thai or Karen. These were 
translated during the course of the interview and only the English translation was 
transcribed verbatim. To facilitate the organisation of the data and the development of a 
coding framework the data was imported into a qualitative data software programme 
(NVivo10). The recordings and transcripts were crosschecked for accuracy and then TC 
performed the primary analysis. This involved open coding the interview, focus group and 
field notes data in a thematic and inductive manner and developing a coding framework. 
Subsequent analytical meetings with TL helped refine this framework and led to the 
definition of two major categories namely; ‘the conceptual framing and nature of 
monitoring’, and ‘the practice of monitoring’, which included reference to relational factors.   
 
 
CASE STUDY PROFILES 
 
Case 1:  MORU-clinical trials support group  
MORU is a collaborative partnership between the Faculty of Tropical Medicine, Mahidol 
University, the University of Oxford and the Wellcome Trust, which was established in 1979 
(www.tropmedres.ac). MORU’s main office and laboratories are located within the Faculty 
of Tropical Medicine at Mahidol University in Bangkok, Thailand. Clinical trials take place at 
study sites across Asia and Africa. A ‘Clinical Trials Support Group’ (CTSG) was established at 
MORU in 2008 to provide help, guidance, and support to investigators conducting research 
involving human subjects.  The defining feature and what sets the of the MORU monitoring 
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model apart from standard monitoring models is the way that CTSG is embedded within an 
established research unit. This positioning means that its members are familiar with the 
health research priorities of the unit, can maintain a constant feedback loop between 
themselves and investigators, and understand the diseases and the social context in which 
trials take place. Additional strengths are that all CTSG members are experienced health 
researchers and some have worked in the pharmaceutical industry or with contract research 
organisations.  CTSG members support protocol development, assist with ethics 
submissions, provide project and data management support, deliver training and assist in 
the quality management of trials. The latter includes writing trial specific risk-based 
monitoring plans with investigators and conducting on-site monitoring at defined time 
points. The MORU monitoring model is not without challenges, however, particularly in 
relation to workload, travel logistics and ensuring monitoring activities are adequately 
budgeted for.  
 
Figure 1 illustrates CTSG’s involvement in monitoring a multicentre randomised trial to 
detect in vivo resistance of Plasmodium falciparum to artesunate in patients with 
uncomplicated malaria (Web registration number: NCT01350856).  This trial is part of the 
‘Tracking Resistance to Artemisinin Collaboration’ (TRAC). 
 
Figure 1: Spatial Organisation and Infrastructure of CTSG TRAC monitoring 
 
 
Case 2: EACCR-Network Reciprocal Monitoring Model  
 
The EACCR (www.eaccr.org) is a partnership of 35 institutions in five countries (Tanzania, 
Uganda, Kenya, Sudan, and Ethiopia). This ‘Network of Excellence’ is funded by the 
European and Developing Countries Clinical Trials Partnership and was established in May 
2009.  At its’ inception the potential for strengthening monitoring capacity across partner 
institutions was established as a priority. The vision was to increase capacity for monitoring 
and develop a pragmatic and cost-efficient network-wide monitoring service.  A reciprocal 
monitoring system was designed and set up in 2007 within KEMRI-Wellcome Programme in 
Kilifi Kenya. This novel approach trained study staff to monitor studies and then this pool of 
trained monitors then spent a small portion of their time monitoring each others studies 
within the programme [18]. This system worked well because it enabled knowledge, best 
practice and skill sharing between different studies in the same organization whilst enabling 
the implementation of high quality clinical research monitoring. This approach was then 
taken up by EACCR and further developed for deployment across this network. This 
network-wide monitoring approach, which was launched at the start of 2011, is referred to 
as the EACCR reciprocal monitoring scheme (RMS). It involves two coordinators based in 
Uganda and Kenya and 22 trained monitors nominated by eleven partner institutions.   
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Figure 2:  EACCR Partner Institutes involved in the RMS 
 
The defining features and strengths of the RMS are that it is reciprocal and involves, on a 
part-time basis, health research professionals who have an in depth appreciation of the 
context where trials are conducted.  It is reciprocal in two key ways; firstly it involves 
members of partner institutes monitoring each-others research, secondly it allows 
experienced monitors to share their expertise with novice monitors who have limited 
experience of trial monitoring.  Initial challenges have also helped the scheme to improve its 
logistical functions, and increase its credibility by clarifying the schemes mandate and 
improving communication between the coordinators and investigators.  
 
 
FINDINGS 
 
The accounts given and the observations collected during the fieldwork convey rich 
information about the nature and practice of on-site monitoring. Accordingly our findings 
are presented under two main headings; first we explore participants’ understandings and 
expectations of clinical trial monitoring, and then we examine what they think constitutes 
professional practice with reference to organisational ethos and accountability, monitors’ 
expertise and approach, and the focus of monitoring activities.   
 
 
What is on-site health research monitoring, and what should it be? 
 
We distilled four core elements of monitoring from participants’ accounts (Text Box 1). The 
latter two are of particular interest because they bring to the fore aspects of monitoring 
which are often overlooked. Our data suggest that whilst investigators appreciated the need 
for regulatory and ethics oversight, they want monitoring to be collaborative in nature and 
scientific in focus.  Some investigators related how constructive interactions with monitors 
assuaged their initial fears and changed their perceptions about the value of monitoring. 
Others championed the need for cooperative monitoring as a result of encounters with 
monitors who questioned their intentions from the outset, or prioritised document 
verification and paperwork over observing critical research processes.  
  
“My first experience was…to me actually I felt it was an activity of policing.  I said, "Wow 
well they are going to find faults," ... I thought maybe it's worth hiding something so that 
they not know yeah.  But with time I came to know really it is something very valuable, that I 
needed to be involved in.  It's actually more to support me into the better conduct of the 
studies.”    
Investigator, EACCR 6 
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‘I could see that something was, that a monster was being created…this is the whole area of 
sort of ethics regulation and so and it seemed to be only one direction of travel which was 
more and more heavy questions and demands and requirements and the net result was 
more and more paperwork, more and more time devoted towards it.’   
Investigator, MORU 26  
 
Investigators were keen to be involved in planning monitoring activities and valued the 
input of monitors who “understand what we call the main focus of the study and give credit 
to the investigator who have long experience” (Investigator, MORU 11). They particularly 
appreciated monitors who worked with them to rectify faults and increase research 
capacity.   
 
MORU investigators described how the establishment of the CTSG has allowed them to 
exercise more control over how trials are monitored. They can draw on the expertise of 
CTSG members to ensure that monitoring activities target the greatest risks to participants 
and the most scientifically relevant data points. This has helped them develop a counter 
argument against some of the bureaucracy they believe is hampering the conduct of 
biomedical research. The EACCR reciprocal monitoring scheme was credited with 
strengthening quality management across the network, and appreciated by monitors as 
means of professional development and exchange. Across both case studies much value was 
attributed to a non-threatening ‘shared learning’ style of monitoring, which prioritized the 
resolution of problems.   
 
'…because it's a sort of cooperative monitoring and not hostile, you're much more likely to 
get problems sorted out rather than hidden.’  
Investigator, MORU 17 
 
It was evident that participants wanted monitoring to be scientifically grounded to ensure 
that quality checks are tailored to primary study outcomes. This type of monitoring requires 
monitors to work closely with investigators from the planning stages of studies.  Much 
emphasis was also placed on the need to complement checking activities with tailored 
support and training. Investigators were positive about the need for correction, especially 
when monitors worked with them to improve their work. Participants concurred that the 
purpose of monitoring should be to improve the conduct of health research and increase 
the capacity of researchers and trial sites. In other words monitoring should ‘help sites 
achieve what they are supposed to achieve’ and offer ‘assurance to investigators that they 
are doing things the right way’.  In practice this type of monitoring replaced negative 
associations with more positive views of monitoring.  
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‘Yeah when a monitor they actually come in to help you do your work better, they're not 
coming to police you or to find mistakes…they're coming to help you do your work better.’  
Monitor, EACCR 3 
 
 
The Practice of Monitoring: What constitutes professional practice? 
 
The 'who' of monitoring 
 
Participants’ experiences of monitoring suggest that the organisational ethos of monitoring 
bodies has a bearing on the practice of monitoring. It was evident from participants’ 
accounts that monitors from external bodies sometimes distanced themselves from 
research staff. In contrast EACCR monitors conveyed the notion that ‘we are doing this 
together’, similarly the positioning of the CTSG as an internal monitoring group within 
MORU enhanced interactions between researchers and monitors and increased 
transparency. On the other hand some MORU investigators felt that research staff were 
more ‘alert and ready’ during monitoring visits from external groups. 
 
These observations about interactions between monitors from different organisations and 
investigators raise important points about accountability and professional relationships. 
EACCR monitors for example argued that monitors can identify with the site whilst 
remaining accountable to the study sponsor, and MORU investigators maintained that the 
positioning of the CTSG does not pose a conflict of interest. To the contrary they work 
together more easily because their professional relationship is built on trust and mutual 
understanding. According to a study nurse this prior knowledge reduced the stress 
associated with monitoring but it did not alter the need for correction.  Internal monitors 
applied the same standards as external monitors but their proximity meant that they were 
more accessible and could provide on-going support.  
 
Yeah for me I think it's not so hard because it's not like the investigator is against the 
sponsor.  So it's not like they're trying to identify with you as opposed to the sponsor.  
They're just when they are on the site they're talking we.  We can do this…and the way I see 
it, it's not hard for them to identify with the site.  
 Monitor EACCR, 27  
 
CTSG they will know the protocol very well and they will know us quite well I have to admit 
it, but that doesn't provide conflict of interest…in a way it make us work together easier. 
Investigator MORU, 11 
 
Monitors background, training and expertise and their understanding of the research 
context were viewed as important in terms of professional practice. One investigator said 
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that he judged the value of monitors work by the ‘quality of the information they are able to 
detect’ (Investigator, EACCR 7).  Health professionals with experience of working in research 
were regarded as particularly well equipped to be monitors.  A role, which was also thought 
to require motivation and commitment, attention to detail, good interpersonal and 
communication skills and the ability to apply and interpret ethics guidelines in practice. With 
reference to the latter an investigator emphasised that monitors needed to understand the 
scientific purpose of the research in order to ‘think about the patient's interests and how 
they could advocate for those, or how they could check for those’ (Investigator MORU, 20).    
 
Much value was attributed to context informed monitoring and investigators resented 
monitors who did little to consider cultural norms, logistical limitations and local 
regulations.  
 
‘They come and they have such little time and they will have to do so much so they're in a 
rush and sometimes they're really distressed to try and meet their milestones.  And then the 
other thing that I have seen is inability to understand the culture and even local regulations 
sometimes, harmonising and local regulations and sponsors, SOPs and their own regulations 
back in their country, it's such a big issue.  So they come out and they would like things done 
the way they understand it.  A few times we took it upon ourselves to really train them on 
our culture, what is acceptable, what cannot be done’.   
Investigator EACCR, 10  
 
This investigator is arguing that an appreciation of local norms, customs and regulations is 
prerequisite for effective and professional monitoring practice. Local monitors were 
considered well placed to undertake context informed monitoring, and external monitors 
who demonstrated a willingness to learn rather than simply impose ideas were also highly 
valued. When it comes to the ‘who’ of monitoring what counts is mutual respect, 
communication, professionalism, and maintaining high standards irrespective of the 
positioning of the monitor in regards to the sponsor and researcher.  
 
The 'what' and 'how' of monitoring 
 
When it came to the practicalities of monitoring what counted was getting the focus and the 
approach right.  Focus requires careful planning and CTSG participants stressed the 
importance of developing monitoring plans with investigators. This planning helped them to 
identify the main risks to a study’s integrity with reference to ethics and key study 
outcomes. It helped them differentiate between minor and major errors thereby avoiding 
diverting unwarranted time to rectifying the former.  Focus also involves achieving the right 
balance between paper work and observing research in practice.  
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‘I mean sometimes documents don't, may not give, tell you, give you, the clear picture of 
how things are run.  Sometimes talking to people, asking people questions, seeing what 
people are doing can assure you, can tell you a number of things that you can't see by 
looking at the documents.’ 
Key Informant EACCR, 28 
 
Concerns were raised by investigators about the amount of time monitors (coming from 
long distances) end up spending sitting in rooms verifying files and source documents. It was 
argued that on-site monitoring should not be confined to document review but include 
observational and interactive activities, which allow monitors to gain greater insights into 
how a trial is being implemented and where corrective action is needed.  
 
Two distinct ways of organising monitoring activities were described. One where the 
monitor performs their review presents findings in debriefing meetings, and sends a 
summary report with action points; and the other where the monitor actively engages 
research staff in resolving issues during the on-site visit. The components of monitoring 
visits were similar but the engagement differed.  Investigators expressed preference for the 
latter but also noted that this method was time-consuming and impractical when the 
research clinics are busy.  
 
A monitor’s personal and professional approach was viewed as crucial to promoting positive 
interactions and improving the quality of trials.  
 
 ‘The key thing about successful monitoring is how you present, how the monitor presents 
themselves and involves themselves with the investigators’  
Investigator MORU, 26 
 
Monitors need to gain the trust of investigators and interviewees argued that the best way 
to do this is to work with investigators to improve study conduct. It was evident that 
investigators were anxious about discussing problems or disclosing important information to 
overly critical monitors. One investigator (Investigator EACCR, 7) described how his team’s 
‘fear just melted away’ when they realised that their monitor’s approach (an external CRO 
monitor) was not adversarial ‘you did this wrong, we are going to beat you’, but constructive 
‘he’s like trying to make you improve’.  
 
The core features of a professional approach to monitoring were cited as a commitment to 
high standards, open communication and positive interactions, mutual respect and a 
friendly manner.  Investigators appreciated monitors who maintained high standards in a 
strict and firm manner and worked with them to enhance the quality of their work.  
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DISCUSSION 
 
Our participatory evaluation provides important insights about the practice of international 
on-site monitoring, and the value of utilizing internal and network expertise to enhance trial 
quality. Particular emphasis was given to a cooperative style of monitoring as a means of 
enhancing trust and transparency. Whilst this style of monitoring was associated with the 
EACCR and MORU models, it is important to note that some participants commented 
positively on interactions with CRO monitors. With reference to practice our findings 
suggest that the primary purpose of on-site monitoring is to improve the conduct of health 
research and increase the capacity of researchers and trial sites. Monitoring activities to be 
scientifically grounded, contextually and culturally informed with tailored support and 
training. Skills in the scientific evaluation of trials and a willingness to work closely with 
investigators were viewed as critical for the development of effective risked-based and 
context informed monitoring plans. It was argued that on-site monitoring should combine 
document verification with observational activities, and be complemented by training and 
mentoring to enable investigators to execute necessary corrective actions. Indeed our data 
suggest that the success of monitoring should be measured by corrective action rather than 
by identification of faults. Monitoring reports should only include findings, which could 
significantly impact on the scientific and ethical integrity of the trials.  
 
The main benefits of the MORU and EACCR monitoring models are: 1) Reduced logistical 
costs, 2) Increased site capacity for quality management, 3) Investigators contribution to 
risk-based monitoring plans, 4) Professional development and exchange. The latter is of 
relevance given the increased value attributed in the health sector to ‘Communities of 
Practice’ (CoPs) as a means of encouraging situated learning and the practical application of 
knowledge[23].  CoPs are defined as: ‘groups of people who share a concern, a set of 
problems, or a passion about a topic, and who deepen their knowledge and expertise in this 
area by interacting on an on-going basis’[24]. The challenges relate to questions of 
sustainability and credibility. There is a need to consider the logistics and funding of these 
models to ensure that their benefits are sustainable. Currently both models rely heavily on 
grants rather than charging trials directly for their services. This needs to be remedied in 
order to reduce dependency on external funding.  
 
The strengths of this empirical study are that it contributes to the literature documenting 
good practice at international trial sites in resource-constrained settings. As noted in the 
background section Macefield et al [20] were only able to include 7 multinational trials in 
their systematic review. Given the study design one inherent limitation is the paucity of 
quantitative findings.  Follow up studies will need to systematically collate information on 
trial costs, and provide monitoring report templates.  An additional weakness of our work is 
that we were not able to compare the monitoring reports of studies monitored by MORU 
and EACCR RMS, and other sponsor delegated monitoring groups. A key area for future 
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research will be to conduct a mixed methods study, which evaluates how the EACCR and 
MORU on-site monitoring models work in combination with CSM.  
 
 
CONCLUSIONS 
 
Innovative monitoring models, which prioritise the sensible application of regulations and 
ethical guidelines are imperative to facilitate vital global health research.  The experience 
gained in developing the innovative international models studied in this paper offers 
valuable insights. Both models utilize internal and network wide expertise to improve the 
ethics and quality of clinical research. They demonstrate how monitoring can be a 
constructive exercise rather than threatening process. The value of cooperative relations 
needs more emphasis in this field given that sponsors, investigators and monitors are jointly 
responsible for ensuring that research protects human rights and produces reliable data, 
which can improve human health. 
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Figure 1:  Spatial Organisation and Infrastructure of CTSG TRAC monitoring  
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Figure 2:  EACCR Partner Institutes involved in the RMS 
 
Legend:  
Red Dots:  RMS Coordinating Centres; UVRI, Entebbe Uganda & KEMRI/CDC, 
Kisumu, Kenya 
Yellow Dots:  Initial Training Centre; KEMRI-Wellcome Programme, Kilifi, Kenya  
Blue Dots:  Additional EACCR Institutes involved in EACCR RMS* 
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* 
Tanzania:       
Kilimanjaro Christian Medical Centre  
National Institutes of Medical Research (Muhumbili, Mwanza)                                       
Kenya:             
KEMRI/Walter Reed Project (Kisumu)  
Kenyan Aids Vaccine Initiative (Nairobi) 
Uganda:          
Makerere University (Kampala)  
Uganda Virus Research Institute (Entebbe)  
Nsambya Hospital (Kampala)  
Ethiopia:         
Armauer Hansen Research Institute (Addis Ababa) 
Sudan:             
University of Khartoum  
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Table 1:  Participants Demographic Characteristics 
 
 
Characteristics 
MORU Case study  
(n=26) 
EACCR Case study 
(n=30) 
Group 1 
(Monitors and KIs)  
(n=11) 
Group 2 
 (Trial team members) 
(n=15) 
Group 1 
 
(n=24) 
Group 2 
 
(n=6) 
Professional background  
Medical Doctor 
Nurse 
Other Health Professional 
Biomedical Scientist 
Social Scientist 
 
 
5 
2 
1 
3 
 
 
 
7 
5 
3 
 
 
 
10 
10 
1 
2 
1 
 
2 
 
 
1 
3 
Research Experience in years 
0-5 
6-10 
10-20 
20+ 
 
 
1 
2 
6 
2 
 
7 
4 
2 
2 
 
5 
14 
5 
 
3 
3 
Gender 
Female 
Male 
 
 
5 
6 
 
8 
7 
 
14 
10 
 
2 
4 
Age Range 
18-24 
25-44 
45-64 
 
 
1 
5 
5 
 
2 
10 
3 
 
 
22 
2 
 
 
6 
Nationality 
Bengali 
British 
Burmese/Karen 
Cambodian 
Dutch 
French 
Indian 
Kenyan 
Malaysian 
Sudanese 
Tanzanian 
Thai 
Ugandan 
 
 
 
3 
 
 
1 
 
1 
1 
 
1 
 
4 
 
2 
 
9 
1 
 
 
 
 
 
 
 
3 
 
 
 
 
 
 
 
 
11 
 
2 
5 
 
6 
 
 
 
 
 
 
 
 
4 
 
 
 
 
2 
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Text Box 1: Elements of Monitoring 
 
 
 Ensuring protocol, ethics and 
regulatory compliance  and 
increasing transparency 
 
“Monitoring is an act of ensuring that data is collected, reported and documented.  Yeah, you know according to the 
regulatory standards and ethical standards that exist internationally and locally”. Monitor EACCR, 2 
 
“Monitoring is a process through which I ensure that the processes within the study have been done in compliance 
with the protocol, the SOPs and the ICH GCP guidelines… with the documents that we know like our Bibles”. 
Investigator, EACCR 8 
 
“So monitor is part of these complicated bodies that try to transparent the studies… “ Investigator MORU, 11 
 
“The purpose of monitoring is to make sure all the documents are being recorded accurately and the participants’ 
safety, it is protect d”.  Monitor EACCR, 5 
 
“...it's that process of evaluating or assessing the conduct of a trial…. but with emphasis on participants’ well-being 
and rights…it’s more an assurance to investigators that you are doing things the right way… so it's quite supportive 
to the investigator team and then it includes the spirit of science to get the best quality data.”  Monitor EACCR, 4 
 
“… overseeing whether the things are being done well in terms of the regulations and the ethics and I swear on top 
of that helping the site to actually achieve what it's supposed to achieve”.  Investigator EACCR, 10 
 
“…the approach definitely should be helping the team not only figuring out the errors…so it should be 
complimentary.  I mean supporting the team. That would be one thing…then I think too much paperwork, 
documentation.  Rather they should focus on scientific aspects.”  Investigator MORU, 25 
 
“Monitors may not necessarily organise a full training programme but I think that it's useful informally because 
there's a lot of it which has very formal kind of feel to it, but it doesn't have to be.  There can be interactions with 
the staff and you can use those interactions to explain why certain things are important.”  Monitor MORU, 18 
 
“So I suppose it's an ongoing review of conduct of a trial and data collection with the purpose of assuring trial 
quality, data quality and protecting interests of the patients I suppose…in practice I think it's still leans too much 
towards checking the paper.”  Investigator MORU, 20 
 
 
 Protecting study participants 
rights and safety  
 
 
 
 Evaluating the science  and 
increasing data accuracy 
 
 
 Supporting and training staff  
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ABSTRACT 
 
Objectives  
To evaluate and determine the value of monitoring models developed by the Mahidol 
Oxford Tropical Research Unit and the East African Consortium for Clinical Research, 
consider how this can be measured and explore monitors and investigators experiences of 
and views about the nature, purpose and practice of monitoring.  
 
Research Design  
The monitoring model case studies represent interventions aimed at changing practice 
hence a participatory action research methodology was applied and 34 interviews, 5 focus 
groups and observations of monitoring activities conducted.  
 
Setting and Participants 
Fieldwork occurred in the places where the monitoring models are coordinated and applied 
in Thailand, Cambodia, Uganda and Kenya. Participants included those coordinating the 
monitoring schemes, monitors, senior investigators and research staff.   
 
Analysis 
Transcribed textual data from field notes, interviews and focus groups was imported into a 
qualitative data software programme (NVIVO 10) and analysed inductively and thematically 
by a qualitative researcher. The initial coding framework was reviewed internally and two 
main categories emerged from the subsequent interrogation of the data.  
 
Results  
The categories that were identified related to the conceptual framing and nature of 
monitoring, and the practice of monitoring, including relational factors. Particular emphasis 
was give to the value of a scientific and cooperative style of monitoring as a means of 
enhancing data quality, trust and transparency. In terms of practice the primary purpose of 
monitoring was defined as improving the conduct of health research and increasing the 
capacity of researchers and trial sites.  
 
Conclusions 
The models studied utilize internal and network wide expertise to improve the ethics and 
quality of clinical research. They demonstrate how monitoring can be a scientific and 
constructive exercise rather than threatening process. The value of cooperative relations 
needs to given more emphasis in monitoring activities, which seek to ensure that research 
protects human rights and produces reliable data.  
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ARTICLE SUMMARY 
 
Article Focus 
• Escalating bureaucracy and regulatory burden is increasing the costs of conducting 
trials, and deterring researchers from conducting high quality science 
• There is significant interest in innovative monitoring models which distil the essence 
of regulatory guidelines in a workable and scientific manner  
• We examined two models developed in international health settings to document 
their implementation, describe the challenges encountered and the good practices 
developed, and increase our understanding of the purpose of monitoring.   
Key Messages 
• More emphasis needs to be placed on the cooperative nature of monitoring and the 
need for monitoring practice to have a clear scientific focus 
• The primary purpose of on-site monitoring is to improve the conduct of health 
research and increase the capacity of researchers and trial sites, and the success of 
monitoring should be measured by corrective action rather than by identification of 
faults 
• There is a need for mixed-methods research to evaluate a combined approach of 
cooperative and scientifically guided on-site monitoring and central statistical 
monitoring 
Strengths and Limitations 
• Addresses a gap in the literature on on-site monitoring in low-income and middle 
income settings 
• Lack of focus on and access to quantitative data which could be collated from 
monitoring reports and plans, and budgetary documents outlining trials costs 
• Unable to compare the monitoring reports of studies monitored by our case studies 
and other sponsor delegated monitoring groups. 
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BACKGROUND  
 
In the field of health research the practice of monitoring has become associated with 
compliance with the  ‘International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use’-Good Clinical Practice 
Guidelines’ (ICH-GCP), and related Federal (United States) and European trial regulations [1-
4]. In ICH-GCP sponsors are delegated responsibility for quality management of which 
monitoring is an integral component. Monitoring is defined as: ‘The act of overseeing the 
progress of a clinical trial, and of ensuring that it is conducted, recorded, and reported in 
accordance with the protocol, Standard Operating Procedures (SOPs), Good Clinical Practice 
(GCP), and the applicable regulatory requirements’ [1]. Section 5.18 of ICH-GCP emphasises 
that the main purpose of monitoring is to verify that the rights and well being of human 
participants are protected. Whilst this overarching ethical purpose is reflected in the 
detailed ICH-GCP guidance, the intrinsic emphasis on record keeping can serve to obscure 
this primary purpose.  
 
Escalating bureaucracy and regulatory burden is increasing the costs of conducting trials, 
and deterring researchers from conducting high quality science [5-7]. Whilst the role of ICH-
GCP in improving quality is widely acknowledged there are questions about its’ application 
in health research, specifically in trials not involving investigational medicinal products [8].  
It is argued that the well-intended values and principles of ICH-GCP have become hampered 
by bureaucracy and misapplication [9 ,10]. An associated ‘tick box’ standard is considered to 
divert attention away from key questions about the ethical process, study endpoints and 
data validity. Delegating monitoring activities to ‘contract research organisations’ (CROs) 
can extenuate this bureaucracy and lead to the misconception that ICH-GCP is highly 
complex and only achievable with huge resources [9]. This can be particularly detrimental to 
research undertaken in low and middle income countries where competitive market forces 
have resulted in clinical research becoming more driven by profit than local health needs 
[11].    
 
ICH-GCP requires that trials should be monitored according to the complexity and nature of 
the trial. The European Medicines Agency and the Food and Drugs Administration have 
released new guidance documents, which encourage sponsors to apply a risk and 
complexity assessment to trials. The aim is to reduce logistical and financial burdens of 
conducting 100% data validation [12 ,13]. This approach was endorsed at the Toronto 
‘Sensible Guidelines Meeting’ in May 2012 [14].  Increasing attention is therefore being paid 
to rationalising monitoring activities to reflect the risks posed to participants, and to ensure 
trials generate accurate data to support decision-making about the safety, efficacy or 
effectiveness of new products and health interventions [15].  
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Central statistical monitoring applied remotely through advanced statistical and 
bioinformatics methods, is proposed as a way of achieving the latter, particularly in multi-
site trials [16 ,17]. Baigent et al cite the following taxonomy of errors affecting trials 1) 
Design Error/Procedural Error 2) Recording Error 3) Fraud, and 4) Analytical Error [17] . They 
argue that on-site monitoring should target errors, requiring due attention at specific trial 
sites. Hence central statistical monitoring is not a stand-alone solution but needs to be 
complemented by proactive on-site monitoring. Experience shows that proactive on-site 
monitoring (e.g. peer-review) can enhance the quality of data and trial processes (e.g. 
participant consent) [18 ,19].  
 
Diverse opinion exists amongst investigators, sponsors and regulators about the definition 
and organisation of monitoring. Points of debate are the balance between central statistical 
monitoring and on-site monitoring, the difference between audit and monitoring, and who 
should undertake these activities. Be it external CROs, in-house pharmaceutical monitors, or 
quality management teams embedded at trial sites. In this discussion there is a dearth of 
literature from international settings. Macefield et al’s recent systematic review of on-site 
monitoring methods for health care randomised controlled trials was only able to include 7 
multi-national articles[20]. They concluded that there was a paucity of evidence and a need 
for further evaluation trials.  
 
In our research we evaluated 2 innovative monitoring models, which are being implemented 
by Mahidol Oxford Tropical Medicine Research Unit in Thailand and by the East African 
Consortium for Clinical Research. Our aims were to observe the approach of these models, 
consider how this could be measured and explore monitors and investigators experiences of 
and views about the nature, purpose and practice of monitoring.  
 
METHODS  
 
Research Design  
 
We used a case study approach to evaluate the Thai unit’s and African consortia’s 
monitoring models in their real life contexts [21]. The case studies represent interventions 
which aim to change and improve practice therefore we applied a participatory 
methodological approach akin to action research [22]. Our research team included 
representatives from the case studies who could act on interim findings during the course of 
the research. A qualitative researcher, who did not occupy an active or a collaborative role 
in the monitoring case studies, coordinated the study. The researcher spent two weeks with 
members of each monitoring case study, during these fieldwork visits she observed 
monitoring activities, participated in a training workshop, reviewed documentary sources, 
and interviewed investigators and monitors associated with the case studies.  
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Study Participants 
 
The sample was drawn purposively in order to select ‘information rich’ representatives from 
two groups: 1) Those actively involved in the development, coordination and 
implementation of the monitoring case studies, and 2) Investigators and research staff 
whose work is being monitored by the monitoring case studies.  The first group includes 
monitors and key informants some of who are senior researchers within the Thai 
programme and the East African Consortia networks. Potential participants were informed 
about the purpose of the study and related research activities verbally and provided with 
study information sheet in advance of the researcher’s fieldwork visits. At the Thai 
programme the Researcher also presented an overview of the study at the central the Thai 
programme offices. The Researcher obtained informed consent from monitors and 
investigators who were willing to be interviewed and agreed to her observing their research 
and monitoring activities. Interviewees were reassured that their contribution would be 
kept confidential, and focus group participants were asked to respect each other’s privacy.  
 
A total of 56 participants were recruited (Group 1=35, Group 2=21) participants from the 
case studies, 26 from the Thai programme and 30 from the East African Consortia.  Group 1 
comprises 9 key informants  (the Thai programme=5, the East African Consortia= 4) and 26 
(the Thai programme=6, the East African Consortia=20) monitors. In the East African 
Consortia case study all of the monitors were also active researchers. Key informants were 
senior investigators and those with experience of quality management, who had played a 
significant role in the development of the respective monitoring schemes. Group 2 
comprises different cadres of staff: senior investigators (the Thai programme=2), site 
investigators/trial coordinators (the Thai programme=4, the East African Consortia=3) and 
trial staff (the Thai programme=9, the East African Consortia=3) including some who were 
specifically responsible for quality control. Table 1 provides details of participants’ 
demographic characteristics. Of note is that the sample includes highly experienced and 
qualified international research professionals.  
 
Fieldwork  
 
In April 2012 the researcher visited the Thai programme offices and research facilities in 
Bangkok and associated research centres/clinics on the Thai-Burmese border (Shoklo 
Medical Research Unit) and at Pailin District Hospital, Cambodia. All of these research 
facilities were involved in an antimalarial resistance trial and the researcher was able to 
observe monitoring activities at each facility. Interviews were held with 8 trial investigators, 
5 key informants and 6 monitors. Two group interviews with members of trial staff based at 
Thai-Burmese border clinics were conducted, one with two participants and the other with 
5.  Thai and Karen translators helped facilitate the group interviews and 2 individual 
interviews with Thai researchers.   
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In May 2012 the researcher travelled to sites connected with the East African Consortia 
monitoring case study and observed a workshop for the East African Consortia monitors. In 
Uganda she visited the Ugandan Virus Research Institute, the International AIDS Vaccine 
Initiative and Medical Research Council offices in Entebbe and observed a two-day 
monitoring visit of an observational HIV treatment trial at Masaka Referral Hospital. In 
Kenya she accompanied two monitors on a three day monitoring visit of an HIV prevention 
trial for sero-discordant couples. During the East African Consortia fieldwork 6 investigators, 
4 key informants and 6 monitors were interviewed. Three group interviews were conducted 
with 15 (4, 5, 6) monitors during a two day monitors training and feedback workshop held in 
Nairobi in May 2012. This workshop provided rich insights into the challenges and successes 
experienced by the East African Consortia monitors. 
 
Across both case studies 34 individual interviews were conducted with 12 investigators, 9 
key informants and 13 monitors, and 2 focus groups with investigators and 3 with monitors.  
The interviews covered a wide range of topics including the history, purpose and value of 
the monitoring models, exp riences gained and practical and ethical challenges 
encountered during their implementation and, the definition of monitoring and how to 
measure or evaluate good practice.  
 
Analysis 
 
Data constituted of field notes, interview and focus groups recordings and transcripts, 
monitoring reports and other documents relating to the case studies. Recordings were 
transcribed verbatim with the exception of oral contributions in Thai or Karen. These were 
translated during the course of the interview and only the English translation was 
transcribed verbatim. To facilitate the organisation of the data and the development of a 
coding framework the anonymised data was imported into a qualitative data software 
programme (NVivo10). The recordings and transcripts were crosschecked for accuracy and 
then TC performed the primary analysis. This involved open coding the interview, focus 
group and field notes data in a thematic and inductive manner and developing a coding 
framework. Subsequent analytical meetings with research team helped refine this 
framework and led to the definition of two major categories namely; ‘the conceptual 
framing and nature of monitoring’, and ‘the practice of monitoring’, which included 
reference to relational factors.   
 
 
CASE STUDY PROFILES 
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Case 1:  The Thai programme-clinical trials support group  
The Thai programme is a collaborative partnership between the Faculty of Tropical 
Medicine, Mahidol University, the University of Oxford and the Wellcome Trust, which was 
established in 1979 (www.tropmedres.ac). The Thai programme’s main office and 
laboratories are located within the Faculty of Tropical Medicine at Mahidol University in 
Bangkok, Thailand. Clinical trials take place at study sites across Asia and Africa. A ‘Clinical 
Trials Support Group’ was established at the Thai programme in 2008 to provide help, 
guidance, and support to investigators conducting research involving human subjects.  The 
defining feature and what sets the Thai programme monitoring model apart from standard 
monitoring models is the way that clinical trial support group is embedded within an 
established research unit. This positioning means that its members are familiar with the 
health research priorities of the unit, can maintain a constant feedback loop between 
themselves and investigators, and understand the diseases and the social context in which 
trials take place. Additional strengths are that all clinical trial support group members are 
experienced health researchers and some have worked in the pharmaceutical industry or 
with contract research organisations.  Clinical trial support group members support protocol 
development, assist with ethics submissions, provide project and data management 
support, deliver training and assist in the quality management of trials. The latter includes 
writing trial specific risk-based monitoring plans with investigators and conducting on-site 
monitoring at defined time points. The Thai programme’s monitoring model is not without 
challenges, however, particularly in relation to workload, travel logistics and ensuring 
monitoring activities are adequately budgeted for.  
 
Figure 1 illustrates clinical trial support group’s involvement in monitoring a multicentre 
randomised trial to detect in vivo resistance of Plasmodium falciparum to artesunate in 
patients with uncomplicated malaria (Web registration number: NCT01350856).  This trial is 
part of the ‘Tracking Resistance to Artemisinin Collaboration’ (TRAC). 
 
Figure 1: Spatial Organisation and Infrastructure of clinical trial support group TRAC 
monitoring 
 
 
Case 2: The East African Consortia Reciprocal Monitoring Model  
 
The East Africa Consortium for Clinical Research (www.eaccr.org) is a partnership of 35 
institutions in five countries (Tanzania, Uganda, Kenya, Sudan, and Ethiopia). This ‘Network 
of Excellence’ is funded by the European and Developing Countries Clinical Trials Partnership 
and was established in May 2009.  At its’ inception the potential for strengthening 
monitoring capacity across partner institutions was established as a priority. The vision was 
to increase capacity for monitoring and develop a pragmatic and cost-efficient network-
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wide monitoring service.  A reciprocal monitoring system was designed and set up in 2007 
within KEMRI-Wellcome Programme in Kilifi Kenya. This novel approach trained study staff 
to monitor studies and then this pool of trained monitors then spent a small portion of their 
time monitoring each others studies within the programme [18]. This system worked well 
because it enabled knowledge, best practice and skill sharing between different studies in 
the same organization whilst enabling the implementation of high quality clinical research 
monitoring. This approach was then taken up by the East African Consortia and further 
developed for deployment across this network. This network-wide monitoring approach, 
which was launched at the start of 2011, is referred to as the East Africa Consortia for 
Clinical Research Scheme reciprocal monitoring scheme. It involves two coordinators based 
in Uganda and Kenya and 22 trained monitors nominated by eleven partner institutions.   
 
Figure 2:  the East African Consortia Partner Institutes involved in the RMS 
 
The defining features and strengths of the reciprocal monitoring are of course that it is 
‘reciprocal’ and thereby involves, on a part-time basis, health research professionals who 
have an in depth appreciation of the context where trials are conducted.  It is reciprocal in 
two key ways; firstly it involves members of partner institutes monitoring each-others 
research, secondly it allows experienced monitors to share their expertise with novice 
monitors who have limited experience of trial monitoring.  Initial challenges have also 
helped the scheme to improve its logistical functions, and increase its credibility by clarifying 
the schemes mandate and improving communication between the coordinators and 
investigators.  
 
 
FINDINGS 
 
The accounts given and the observations collected during the fieldwork convey rich 
information about the nature and practice of on-site monitoring. Accordingly our findings 
are presented under two main headings; first we explore participants’ understandings and 
expectations of clinical trial monitoring, and then we examine what they think constitutes 
professional practice with reference to organisational ethos and accountability, monitors’ 
expertise and approach, and the focus of monitoring activities.   
 
 
What is on-site health research monitoring, and what should it be? 
 
We distilled four core elements of monitoring from participants’ accounts (Text Box 1). The 
latter two are of particular interest because they bring to the fore aspects of monitoring 
which are often overlooked. Our data suggest that whilst investigators appreciated the need 
for regulatory and ethics oversight, they want monitoring to be collaborative in nature and 
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scientific in focus.  Some investigators related how constructive interactions with monitors 
assuaged their initial fears and changed their perceptions about the value of monitoring. 
Others championed the need for cooperative monitoring as a result of encounters with 
monitors who questioned their intentions from the outset, or prioritised document 
verification and paperwork over observing critical research processes.  
  
“My first experience was…to me actually I felt it was an activity of policing.  I said, "Wow 
well they are going to find faults," ... I thought maybe it's worth hiding something so that 
they not know yeah.  But with time I came to know really it is something very valuable, that I 
needed to be involved in.  It's actually more to support me into the better conduct of the 
studies.”    
Investigator, the East African Consortia 6 
 
‘I could see that something was, that a monster was being created…this is the whole area of 
sort of ethics regulation and so and it seemed to be only one direction of travel which was 
more and more heavy questions and demands and requirements and the net result was 
more and more paperwork, mor  and more time devoted towards it.’   
Investigator, the Thai programme 26  
 
Investigators were keen to be involved in planning monitoring activities and valued the 
input of monitors who “understand what we call the main focus of the study and give credit 
to the investigator who have long experience” (Investigator, the Thai programme 11). They 
particularly appreciated monitors who worked with them to rectify faults and increase 
research capacity.   
 
The Thai programme investigators described how the establishment of the clinical trial 
support group has allowed them to exercise more control over how trials are monitored. 
They can draw on the expertise of clinical trial support gr up members to ensure that 
monitoring activities target the greatest risks to participants and the most scientifically 
relevant data points. This has helped them develop a counter argument against some of the 
bureaucracy they believe is hampering the conduct of biomedical research. The East African 
Consortia reciprocal monitoring scheme was credited with strengthening quality 
management across the network, and appreciated by monitors as means of professional 
development and exchange. Across both case studies much value was attributed to a non-
threatening ‘shared learning’ style of monitoring, which prioritized the resolution of 
problems.   
 
'…because it's a sort of cooperative monitoring and not hostile, you're much more likely to 
get problems sorted out rather than hidden.’  
Investigator, the Thai programme 17 
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It was evident that participants wanted monitoring to be scientifically grounded to ensure 
that quality checks are tailored to primary study outcomes. This type of monitoring requires 
monitors to work closely with investigators from the planning stages of studies.  Much 
emphasis was also placed on the need to complement checking activities with tailored 
support and training. Investigators were positive about the need for correction, especially 
when monitors worked with them to improve their work. Participants concurred that the 
purpose of monitoring should be to improve the conduct of health research and increase 
the capacity of researchers and trial sites. In other words monitoring should ‘help sites 
achieve what they are supposed to achieve’ and offer ‘assurance to investigators that they 
are doing things the right way’.  In practice this type of monitoring replaced negative 
associations with more positive views of monitoring.  
 
 
‘Yeah when a monitor they actually come in to help you do your work better, they're not 
coming to police you or to find mistakes…they're coming to help you do your work better.’  
Monitor, the East African Consortia 3 
 
 
The Practice of Monitoring: What constitutes professional practice? 
 
The 'who' of monitoring 
 
Participants’ experiences of monitoring suggest that the organisational ethos of monitoring 
bodies has a bearing on the practice of monitoring. It was evident from participants’ 
accounts that monitors from external bodies sometimes distanced themselves from 
research staff. In contrast the East African Consortia monitors conveyed the notion that ‘we 
are doing this together’, similarly the positioning of the clinical trial support group as an 
internal monitoring group within the Thai programme enhanced interactions between 
researchers and monitors and increased transparency. On the other hand some the Thai 
programme investigators felt that research staff were more ‘alert and ready’ during 
monitoring visits from external groups. 
 
These observations about interactions between monitors from different organisations and 
investigators raise important points about accountability and professional relationships. The 
East African Consortia monitors for example argued that monitors can identify with the site 
whilst remaining accountable to the study sponsor, and the Thai programme investigators 
maintained that the positioning of the clinical trial support group does not pose a conflict of 
interest. To the contrary they work together more easily because their professional 
relationship is built on trust and mutual understanding. According to a study nurse this prior 
knowledge reduced the stress associated with monitoring but it did not alter the need for 
correction.  Internal monitors applied the same standards as external monitors but their 
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proximity meant that they were more accessible and could provide on-going support.  
 
Yeah for me I think it's not so hard because it's not like the investigator is against the 
sponsor.  So it's not like they're trying to identify with you as opposed to the sponsor.  
They're just when they are on the site they're talking we.  We can do this…and the way I see 
it, it's not hard for them to identify with the site.  
 Monitor the East African Consortia, 27  
 
clinical trial support group they will know the protocol very well and they will know us quite 
well I have to admit it, but that doesn't provide conflict of interest…in a way it make us work 
together easier. 
Investigator the Thai programme, 11 
 
Monitors background, training and expertise and their understanding of the research 
context were viewed as important in terms of professional practice. One investigator said 
that he judged the value of monitors work by the ‘quality of the information they are able to 
detect’ (Investigator, the East African Consortia 7).  Health professionals with experience of 
working in research were regarded as particularly well equipped to be monitors.  A role, 
which was also thought to require motivation and commitment, attention to detail, good 
interpersonal and communication skills and the ability to apply and interpret ethics 
guidelines in practice. With reference to the latter an investigator emphasised that monitors 
needed to understand the scientific purpose of the research in order to ‘think about the 
patient's interests and how they could advocate for those, or how they could check for those’ 
(Investigator the Thai programme, 20).    
 
Much value was attributed to context informed monitoring and investigators resented 
monitors who did little to consider cultural norms, logistical limitations and local 
regulations.  
 
‘They come and they have such little time and they will have to do so much so they're in a 
rush and sometimes they're really distressed to try and meet their milestones.  And then the 
other thing that I have seen is inability to understand the culture and even local regulations 
sometimes, harmonising and local regulations and sponsors, SOPs and their own regulations 
back in their country, it's such a big issue.  So they come out and they would like things done 
the way they understand it.  A few times we took it upon ourselves to really train them on 
our culture, what is acceptable, what cannot be done’.   
Investigator the East African Consortia, 10  
 
This investigator is arguing that an appreciation of local norms, customs and regulations is 
prerequisite for effective and professional monitoring practice. Local monitors were 
considered well placed to undertake context informed monitoring, and external monitors 
who demonstrated a willingness to learn rather than simply impose ideas were also highly 
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valued. When it comes to the ‘who’ of monitoring what counts is mutual respect, 
communication, professionalism, and maintaining high standards irrespective of the 
positioning of the monitor in regards to the sponsor and researcher.  
 
The 'what' and 'how' of monitoring 
 
When it came to the practicalities of monitoring what counted was getting the focus and the 
approach right.  Focus requires careful planning and clinical trial support group participants 
stressed the importance of developing monitoring plans with investigators. This planning 
helped them to identify the main risks to a study’s integrity with reference to ethics and key 
study outcomes. It helped them differentiate between minor and major errors thereby 
avoiding diverting unwarranted time to rectifying the former.  Focus also involves achieving 
the right balance between paper work and observing research in practice.  
 
 
‘I mean sometimes documents don't, may not give, tell you, give you, the clear picture of 
how things are run.  Sometimes talking to people, asking people questions, seeing what 
people are doing can assure you, can tell you a number of things that you can't see by 
looking at the documents.’ 
Key Informant the East African Consortia, 28 
 
Concerns were raised by investigators about the amount of time monitors (coming from 
long distances) end up spending sitting in rooms verifying files and source documents. It was 
argued that on-site monitoring should not be confined to document review but include 
observational and interactive activities, which allow monitors to gain greater insights into 
how a trial is being implemented and where corrective action is needed.  
 
Two distinct ways of organising monitoring activities were described. One where the 
monitor performs their review presents findings in debriefing meetings, and sends a 
summary report with action points; and the other where the monitor actively engages 
research staff in resolving issues during the on-site visit. The components of monitoring 
visits were similar but the engagement differed.  Investigators expressed preference for the 
latter but also noted that this method was time-consuming and impractical when the 
research clinics are busy.  
 
A monitor’s personal and professional approach was viewed as crucial to promoting positive 
interactions and improving the quality of trials.  
 
 ‘The key thing about successful monitoring is how you present, how the monitor presents 
themselves and involves themselves with the investigators’  
Investigator the Thai programme, 26 
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Monitors need to gain the trust of investigators and interviewees argued that the best way 
to do this is to work with investigators to improve study conduct. It was evident that 
investigators were anxious about discussing problems or disclosing important information to 
overly critical monitors. One investigator (Investigator the East African Consortia, 7) 
described how his team’s ‘fear just melted away’ when they realised that their monitor’s 
approach (an external CRO monitor) was not adversarial ‘you did this wrong, we are going to 
beat you’, but constructive ‘he’s like trying to make you improve’.  
 
The core features of a professional approach to monitoring were cited as a commitment to 
high standards, open communication and positive interactions, mutual respect and a 
friendly manner.  Investigators appreciated monitors who maintained high standards in a 
strict and firm manner and worked with them to enhance the quality of their work.  
 
 
DISCUSSION 
 
Our participatory evaluation provides important insights about the practice of international 
on-site monitoring, and the value of utilizing internal and network expertise to enhance trial 
quality. Particular emphasis was given to a cooperative style of monitoring as a means of 
enhancing trust and transparency. Whilst this style of monitoring was associated with the 
East African Consortia and the Thai programme models, it is important to note that some 
participants commented positively on interactions with CRO monitors. With reference to 
practice our findings suggest that the primary purpose of on-site monitoring is to improve 
the conduct of health research and increase the capacity of researchers and trial sites. 
Monitoring activities to be scientifically grounded, contextually and culturally informed with 
tailored support and training. Skills in the scientific evaluation of trials and a willingness to 
work closely with investigators were viewed as critical for the development of effective 
risked-based and context informed monitoring plans. It was argued that on-site monitoring 
should combine document verification with observational activities, and be complemented 
by training and mentoring to enable investigators to execute necessar  corrective actions. 
Indeed our data suggest that the success of monitoring should be measured by corrective 
action rather than by identification of faults. Monitoring reports should only include 
findings, which could significantly impact on the scientific and ethical integrity of the trials.  
 
The main benefits of the Thai programme and the East African Consortia monitoring models 
are: 1) Reduced logistical costs, 2) Increased site capacity for quality management, 3) 
Investigators contribution to risk-based monitoring plans, 4) Professional development and 
exchange. The latter is of relevance given the increased value attributed in the health sector 
to ‘Communities of Practice’ as a means of encouraging situated learning and the practical 
application of knowledge[23].  Communities of practice are defined as: ‘groups of people 
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who share a concern, a set of problems, or a passion about a topic, and who deepen their 
knowledge and expertise in this area by interacting on an on-going basis’[24]. The 
challenges relate to questions of sustainability and credibility. There is a need to consider 
the logistics and funding of these models to ensure that their benefits are sustainable. 
Currently both models rely heavily on grants rather than charging trials directly for their 
services. This needs to be remedied in order to reduce dependency on external funding.  
 
The strengths of this empirical study are that it contributes to the literature documenting 
good practice at international trial sites in resource-constrained settings. As noted in the 
background section Macefield et al [20] were only able to include 7 multinational trials in 
their systematic review. Given the study design one inherent limitation is the paucity of 
quantitative findings.  Follow up studies will need to systematically collate information on 
trial costs, and provide monitoring report templates.  An additional weakness of our work is 
that we were not able to compare the monitoring reports of studies monitored by the Thai 
programme and the East African Consortia reciprocal monitoring scheme, and other sponsor 
delegated monitoring groups. A key area for future research will be to conduct a mixed 
methods study, which evaluates how the East African Consortia and the Thai programme 
on-site monitoring models work in combination with central monitoring systems.  
 
 
CONCLUSIONS 
 
Innovative monitoring models, which prioritise the sensible application of regulations and 
ethical guidelines are imperative to facilitate vital global health research.  The experience 
gained in developing the innovative international models studied in this paper offers 
valuable insights and examples of alternative approaches. Both models utilize internal and 
network wide expertise to improve the ethical conduct and data quality of clinical research. 
They demonstrate how monitoring can be a constructive exercise rather than threatening 
process. The value of cooperative relations needs more emphasis in this field given that 
sponsors, investigators and monitors are jointly responsible for ensuring that research 
protects human rights and produces reliable data, which can improve human health. 
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FIGURE LEGENDS 
Figure 1: Spatial Organisation and Infrastructure of clinical trial support group TRAC 
monitoring 
Figure 2:  The East African Consortia Partner Institutes involved in the RMS 
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Table 1:  Participants Demographic Characteristics 
 
 
Characteristics 
The Thai Unit 
(n=26) 
The East African 
Consortia 
 (n=30) 
Group 1 
(Monitors and KIs)  
(n=11) 
Group 2 
 (Trial team members) 
(n=15) 
Group 1 
 
(n=24) 
Group 2 
 
(n=6) 
Professional background  
Medical Doctor 
Nurse 
Other Health Professional 
Biomedical Scientist 
Social Scientist 
 
 
5 
2 
1 
3 
 
 
 
7 
5 
3 
 
 
 
10 
10 
1 
2 
1 
 
2 
 
 
1 
3 
Research Experience in years 
0-5 
6-10 
10-20 
20+ 
 
 
1 
2 
6 
2 
 
7 
4 
2 
2 
 
5 
14 
5 
 
3 
3 
Gender 
Female 
Male 
 
 
5 
6 
 
8 
7 
 
14 
10 
 
2 
4 
Age Range     
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18-24 
25-44 
45-64 
 
1 
5 
5 
2 
10 
3 
 
22 
2 
 
6 
Nationality 
Bengali 
British 
Burmese/Karen 
Cambodian 
Dutch 
French 
Indian 
Kenyan 
Malaysian 
Sudanese 
Tanzanian 
Thai 
Ugandan 
 
 
 
3 
 
 
1 
 
1 
1 
 
1 
 
4 
 
2 
 
9 
1 
 
 
 
 
 
 
 
3 
 
 
 
 
 
 
 
 
11 
 
2 
5 
 
6 
 
 
 
 
 
 
 
 
4 
 
 
 
 
2 
 
 
 
 
Text Box 1: Elements of Monitoring 
 
 
 Ensuring protocol, 
ethics and regulatory 
compliance  and 
increasing 
transparency 
 
“Monitoring is an act of ensuring that data is collected, reported and 
documented.  Yeah, you know according to the regulatory standards 
and ethical standards that exist internationally and locally”. Monitor 
EACCR, 2 
 
“Monitoring is a process through which I ensure that the processes 
within the study have been done in compliance with the protocol, the 
SOPs and the ICH GCP guidelines… with the documents that we know 
like our Bibles”. Investigator, EACCR 8 
 
“So monitor is part of these complicated bodies that try to transparent 
the studies… “ Investigator MORU, 11 
 
“The purpose of monitoring is to make sure all the documents are 
being recorded accurately and the participants’ safety, it is protected”.  
Monitor EACCR, 5 
 
“...it's that process of evaluating or assessing the conduct of a trial…. 
but with emphasis on participants’ well-being and rights…it’s more an 
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assurance to investigators that you are doing things the right way… so 
it's quite supportive to the investigator team and then it includes the 
spirit of science to get the best quality data.”  Monitor EACCR, 4 
 
“… overseeing whether the things are being done well in terms of the 
regulations and the ethics and I swear on top of that helping the site 
to actually achieve what it's supposed to achieve”.  Investigator 
EACCR, 10 
 
“…the approach definitely should be helping the team not only figuring 
out the errors…so it should be complimentary.  I mean supporting the 
team. That would be one thing…then I think too much paperwork, 
documentation.  Rather they should focus on scientific aspects.”  
Investigator MORU, 25 
 
“Monitors may not necessarily organise a full training programme but I 
think that it's useful informally because there's a lot of it which has 
very formal kind of feel to it, but it doesn't have to be.  There can be 
interactions with the staff and you can use those interactions to explain 
why certain things are important.”  Monitor MORU, 18 
 
“So I suppose it's an ongoing review of conduct of a trial and data 
collection with the purpose of assuring trial quality, data quality and 
protecting interests of the patients I suppose…in practice I think it's 
still leans too much towards checking the paper.”  Investigator MORU, 
20 
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ABSTRACT 
 
Objectives  
To evaluate and determine the value of monitoring models developed by the Mahidol 
Oxford Tropical Research Unit and the East African Consortium for Clinical Research, 
consider how this value can be measured and explore monitors and investigators 
experiences of and views about the nature, purpose and practice of monitoring.  
 
Research Design  
The monitoring model case studies represent interventions aimed at changing practice 
hence a participatory action research methodology was applied and 34 interviews, 5 focus 
groups and observations of monitoring activities conducted.  
 
Setting and Participants 
Fieldwork occurred in the places where the monitoring models are coordinated and applied 
in Thailand, Cambodia, Uganda and Kenya. Participants included those coordinating the 
monitoring schemes, monitors, senior investigators and research staff.   
 
Analysis 
Transcribed textual data from field notes, interviews and focus groups was imported into a 
qualitative data software programme (NVIVO 10) and analysed inductively and thematically 
by a qualitative researcher. The initial coding framework was reviewed internally and two 
main categories emerged from the subsequent interrogation of the data.  
 
Results  
The categories identified related to the conceptual framing and nature of monitoring, and 
the practice of monitoring, including relational factors. Particular emphasis was give to the 
value of a scientific and cooperative style of monitoring as a means of enhancing data 
quality, trust and transparency. In terms of practice the primary purpose of monitoring was 
defined as improving the conduct or health research and increasing the capacity of 
researchers and trial sites.  
 
Conclusions 
The models studied utilize internal and network wide expertise to improve the ethics and 
quality of clinical research. They demonstrate how monitoring can be a scientific and 
constructive exercise rather than threatening process. The value of cooperative relations 
needs to given more emphasis in monitoring activities, which seek to ensure that research 
protects human rights and produces reliable data.  
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ARTICLE SUMMARY 
 
Article Focus 
• Escalating bureaucracy and regulatory burden is increasing the costs of conducting 
trials, and deterring researchers from conducting high quality science 
• There is significant interest in innovative monitoring models which distil the essence 
of regulatory guidelines in a workable and scientific manner  
• We examined two models developed in international health settings to document 
their implementation, describe the challenges encountered and the good practices 
developed, and increase our understanding of the purpose of monitoring.   
Key Messages 
• More emphasis needs to be placed on the cooperative nature of monitoring and the 
need for monitoring practice to have a clear scientific focus 
• The primary purpose of on-site monitoring is to improve the conduct of health 
research and increase the capacity of researchers and trial sites, and the success of 
monitoring should be measured by corrective action rather than by identification of 
faults 
• There is a need for mixed-methods research to evaluate a combined approach of 
cooperative and scientifically guided on-site monitoring and central statistical 
monitoring 
Strengths and Limitations 
• Addresses a gap in the literature on on-site monitoring in low-income and middle 
income settings 
• Lack of focus on and access to quantitative data which could be collated from 
monitoring reports and plans, and budgetary documents outlining trials costs 
• Unable to compare the monitoring reports of studies monitored by our case studies 
and other sponsor delegated monitoring groups. 
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BACKGROUND  
 
In the field of health research the practice of monitoring has become associated with 
compliance with the  ‘International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use’-Good Clinical Practice 
Guidelines’ (ICH-GCP), and related Federal (United States) and European trial regulations [1-
4]. In ICH-GCP sponsors are delegated responsibility for quality management of which 
monitoring is an integral component. Monitoring is defined as: ‘The act of overseeing the 
progress of a clinical trial, and of ensuring that it is conducted, recorded, and reported in 
accordance with the protocol, Standard Operating Procedures (SOPs), Good Clinical Practice 
(GCP), and the applicable regulatory requirements’ [1]. Section 5.18 of ICH-GCP emphasises 
that the main purpose of monitoring is to verify that the rights and well being of human 
participants are protected. Whilst this overarching ethical purpose is reflected in the 
detailed ICH-GCP guidance, the intrinsic emphasis on record keeping can serve to obscure 
this primary purpose.  
 
Escalating bureaucracy and regulatory burden is increasing the costs of conducting trials, 
and deterring researchers from conducting high quality science [5-7]. Whilst the role of ICH-
GCP in improving quality is widely acknowledged there are questions about its’ application 
in health research, specifically in trials not involving investigational medicinal products [8].  
It is argued that the well-intended values and principles of ICH-GCP have become hampered 
by bureaucracy and misapplication [9 ,10]. An associated ‘tick box’ standard is considered to 
divert attention away from key questions about the ethical process, study endpoints and 
data validity. Delegating monitoring activities to ‘contract research organisations’ (CROs) 
can extenuate this bureaucracy and lead to the misconception that ICH-GCP is highly 
complex and only achievable with huge resources [9]. This can be particularly detrimental to 
research undertaken in low and middle income countries where competitive market forces 
have resulted in clinical research becoming more driven by profit than local health needs 
[11].    
 
ICH-GCP requires that trials should be monitored according to the complexity and nature of 
the trial. The European Medicines Agency and the Food and Drugs Administration have 
released new guidance documents, which encourage sponsors to apply a risk and 
complexity assessment to trials. The aim is to reduce logistical and financial burdens of 
conducting 100% data validation [12 ,13]. This approach was endorsed at the Toronto 
‘Sensible Guidelines Meeting’ in May 2012 [14].  Increasing attention is therefore being paid 
to rationalising monitoring activities to reflect the risks posed to participants, and to ensure 
trials generate accurate data to support decision-making about the safety, efficacy or 
effectiveness of new products and health interventions [15].  
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Central statistical monitoring (CSM), applied remotely through advanced statistical and 
bioinformatics methods, is proposed as a way of achieving the latter, particularly in multi-
site trials [16 ,17]. Baigent et al cite the following taxonomy of errors affecting trials 1) 
Design Error/Procedural Error 2) Recording Error 3) Fraud, and 4) Analytical Error [17] . They 
argue that on-site monitoring should target errors, requiring due attention at specific trial 
sites. Hence CSM is not a stand-alone solution but needs to be complemented by proactive 
on-site monitoring. Experience shows that proactive on-site monitoring (e.g. peer-review) 
can enhance the quality of data and trial processes (e.g. participant consent) [18 ,19].  
 
Diverse opinion exists amongst investigators, sponsors and regulators about the definition 
and organisation of monitoring. Points of debate are the balance between CSM and on-site 
monitoring, the difference between audit and monitoring, and who should undertake these 
activities. Be it external CROs, in-house pharmaceutical monitors, or quality management 
teams embedded at trial sites. In this discussion there is a dearth of literature from 
international settings. Macefield et al’s recent systematic review of on-site monitoring 
methods for health care randomised controlled trials was only able to include 7 multi-
national articles[20]. They concluded that there was a paucity of evidence and a need for 
further evaluation trials.  
 
In our research we evaluated 2 innovative monitoring models, which are being implemented 
by Mahidol Oxford Tropical Medicine Research Unit in Thailand (MORU) and by the East 
African Consortium for Clinical Research (EACCR).  Our aims were to determine the 
valueobserve the approach of these models, consider how this could be measured and 
explore monitors and investigators experiences of and views about the nature, purpose and 
practice of monitoring.  
 
 
METHODS  
 
Research Design  
 
We used a case study approach to evaluate the MORU and EACCR monitoring models in 
their real life contexts [21]. The case studies represent interventions which aim to change 
and improve practice therefore we applied a participatory methodological approach akin to 
action research [22]. Our research team included representatives from the case studies who 
could act on interim findings during the course of the research. A qualitative researcher 
(QR), who did not occupy an active or a collaborative role in the monitoring case studies, 
coordinated the study. The QR spent two weeks with members of each monitoring case 
study, during these fieldwork visits she observed monitoring activities, participated in a 
training workshop, reviewed documentary sources, and interviewed investigators and 
monitors associated with the case studies.  
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Study Participants 
 
The sample was drawn purposively in order to select ‘information rich’ representatives from 
two groups: 1) Those actively involved in the development, coordination and 
implementation of the monitoring case studies, and 2) Investigators and research staff 
whose work is being monitored by the monitoring case studies.  The first group includes 
monitors and key informants (KIs) some of who are senior researchers within the MORU and 
EACCR networks. Potential participants were informed about the purpose of the study and 
related research activities verbally and provided with study information sheet in advance of 
the researcher’s fieldwork visits. At MORU the QR also presented an overview of the study 
at the central MORU offices. The QR obtained informed consent from monitors and 
investigators who were willing to be interviewed and agreed to her observing their research 
and monitoring activities. Interviewees were reassured that their contribution would be 
kept confidential, and focus group participants were asked to respect each other’s privacy.  
 
A total of 56 participants were recruited (Group 1=35, Group 2=21) participants from the 
case studies, 26 from MORU and 30 from EACCR.  Group 1 comprises 9 key informants  
(MORU=5, EACCR= 4) and 26 (MORU=6, EACCR=20) monitors. In the EACCR case study all of 
the monitors were also active researchers. Key informants were senior investigators and 
those with experience of quality management, who had played a significant role in the 
development of the respective monitoring schemes. Group 2 comprises different cadres of 
staff: senior investigators (MORU=2), site investigators/trial coordinators (MORU=4, 
EACCR=3) and trial staff (MORU=9, EACCR=3) including some who were specifically 
responsible for quality control. Table 1 provides details of participants’ demographic 
characteristics. Of note is that the sample includes highly experienced and qualified 
international research professionals.  
 
Fieldwork  
 
In April 2012 the QR visited the MORU offices and research facilities in Bangkok and 
associated research centres/clinics on the Thai-Burmese border (Shoklo Medical Research 
Unit) and at Pailin District Hospital, Cambodia. All of these research facilities were involved 
in an antimalarial resistance trial and the researcher was able to observe monitoring 
activities at each facility. Interviews were held with 8 trial investigators, 5 KIs and 6 
monitors. Two group interviews with members of trial staff based at Thai-Burmese border 
clinics were conducted, one with two participants and the other with 5.  Thai and Karen 
translators helped facilitate the group interviews and 2 individual interviews with Thai 
researchers.   
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In May 2012 the QR travelled to sites connected with the EACCR monitoring case study and 
observed a workshop for EACCR monitors. In Uganda she visited the Ugandan Virus 
Research Institute, the International AIDS Vaccine Initiative and Medical Research Council 
offices in Entebbe and observed a two-day monitoring visit of an observational HIV 
treatment trial at Masaka Referral Hospital. In Kenya she accompanied two monitors on a 
three day monitoring visit of an HIV prevention trial for sero-discordant couples. During the 
EACCR fieldwork 6 investigators, 4 KIs and 6 monitors were interviewed. Three group 
interviews were conducted with 15 (4, 5, 6) monitors during a two day monitors training and 
feedback workshop held in Nairobi in May 2012. This workshop provided rich insights into 
the challenges and successes experienced by EACCR monitors. 
 
Across both case studies 34 individual interviews were conducted with 12 investigators, 9 
key informants and 13 monitors, and 2 focus groups with investigators and 3 with monitors.  
The interviews covered a wide range of topics including the history, purpose and value of 
the monitoring models, experiences gained and practical and ethical challenges 
encountered during their implementation and, the definition of monitoring and how to 
measure or evaluate good practice.  
 
Analysis 
 
Data constituted of field notes, interview and focus groups recordings and transcripts, 
monitoring reports and other documents relating to the case studies. Recordings were 
transcribed verbatim with the exception of oral contributions in Thai or Karen. These were 
translated during the course of the interview and only the English translation was 
transcribed verbatim. To facilitate the organisation of the data and the development of a 
coding framework the anonymised data was imported into a qualitative data software 
programme (NVivo10). The recordings and transcripts were crosschecked for accuracy and 
then TC performed the primary analysis. This involved open coding the interview, focus 
group and field notes data in a thematic and inductive manner and developing a coding 
framework. Subsequent analytical meetings with TL helped refine this framework and led to 
the definition of two major categories namely; ‘the conceptual framing and nature of 
monitoring’, and ‘the practice of monitoring’, which included reference to relational factors.   
 
 
CASE STUDY PROFILES 
 
Case 1:  MORU-clinical trials support group  
MORU is a collaborative partnership between the Faculty of Tropical Medicine, Mahidol 
University, the University of Oxford and the Wellcome Trust, which was established in 1979 
(www.tropmedres.ac). MORU’s main office and laboratories are located within the Faculty 
of Tropical Medicine at Mahidol University in Bangkok, Thailand. Clinical trials take place at 
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study sites across Asia and Africa. A ‘Clinical Trials Support Group’ (CTSG) was established at 
MORU in 2008 to provide help, guidance, and support to investigators conducting research 
involving human subjects.  The defining feature and what sets the of the MORU monitoring 
model apart from standard monitoring models is the way that CTSG is embedded within an 
established research unit. This positioning means that its members are familiar with the 
health research priorities of the unit, can maintain a constant feedback loop between 
themselves and investigators, and understand the diseases and the social context in which 
trials take place. Additional strengths are that all CTSG members are experienced health 
researchers and some have worked in the pharmaceutical industry or with contract research 
organisations.  CTSG members support protocol development, assist with ethics 
submissions, provide project and data management support, deliver training and assist in 
the quality management of trials. The latter includes writing trial specific risk-based 
monitoring plans with investigators and conducting on-site monitoring at defined time 
points. The MORU monitoring model is not without challenges, however, particularly in 
relation to workload, travel logistics and ensuring monitoring activities are adequately 
budgeted for.  
 
Figure 1 illustrates CTSG’s involvement in monitoring a multicentre randomised trial to 
detect in vivo resistance of Plasmodium falciparum to artesunate in patients with 
uncomplicated malaria (Web registration number: NCT01350856).  This trial is part of the 
‘Tracking Resistance to Artemisinin Collaboration’ (TRAC). 
 
Figure 1: Spatial Organisation and Infrastructure of CTSG TRAC monitoring 
 
 
Case 2: EACCR-Network Reciprocal Monitoring Model  
 
The EACCR (www.eaccr.org) is a partnership of 35 institutions in five countries (Tanzania, 
Uganda, Kenya, Sudan, and Ethiopia). This ‘Network of Excellence’ is funded by the 
European and Developing Countries Clinical Trials Partnership and was established in May 
2009.  At its’ inception the potential for strengthening monitoring capacity across partner 
institutions was established as a priority. The vision was to increase capacity for monitoring 
and develop a pragmatic and cost-efficient network-wide monitoring service.  A reciprocal 
monitoring system was designed and set up in 2007 within KEMRI-Wellcome Programme in 
Kilifi Kenya. This novel approach trained study staff to monitor studies and then this pool of 
trained monitors then spent a small portion of their time monitoring each others studies 
within the programme [18]. This system worked well because it enabled knowledge, best 
practice and skill sharing between different studies in the same organization whilst enabling 
the implementation of high quality clinical research monitoring. This approach was then 
taken up by EACCR and further developed for deployment across this network. This 
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network-wide monitoring approach, which was launched at the start of 2011, is referred to 
as the EACCR reciprocal monitoring scheme (RMS). It involves two coordinators based in 
Uganda and Kenya and 22 trained monitors nominated by eleven partner institutions.   
 
Figure 2:  EACCR Partner Institutes involved in the RMS 
 
The defining features and strengths of the RMS are that it is reciprocal and involves, on a 
part-time basis, health research professionals who have an in depth appreciation of the 
context where trials are conducted.  It is reciprocal in two key ways; firstly it involves 
members of partner institutes monitoring each-others research, secondly it allows 
experienced monitors to share their expertise with novice monitors who have limited 
experience of trial monitoring.  Initial challenges have also helped the scheme to improve its 
logistical functions, and increase its credibility by clarifying the schemes mandate and 
improving communication between the coordinators and investigators.  
 
 
FINDINGS 
 
The accounts given and the observations collected during the fieldwork convey rich 
information about the nature and practice of on-site monitoring. Accordingly our findings 
are presented under two main headings; first we explore participants’ understandings and 
expectations of clinical trial monitoring, and then we examine what they think constitutes 
professional practice with reference to organisational ethos and accountability, monitors’ 
expertise and approach, and the focus of monitoring activities.   
 
 
What is on-site health research monitoring, and what should it be? 
 
We distilled four core elements of monitoring from participants’ accounts (Text Box 1). The 
latter two are of particular interest because they bring to the fore aspects of monitoring 
which are often overlooked. Our data suggest that whilst investigators appreciated the need 
for regulatory and ethics oversight, they want monitoring to be collaborative in nature and 
scientific in focus.  Some investigators related how constructive interactions with monitors 
assuaged their initial fears and changed their perceptions about the value of monitoring. 
Others championed the need for cooperative monitoring as a result of encounters with 
monitors who questioned their intentions from the outset, or prioritised document 
verification and paperwork over observing critical research processes.  
  
“My first experience was…to me actually I felt it was an activity of policing.  I said, "Wow 
well they are going to find faults," ... I thought maybe it's worth hiding something so that 
they not know yeah.  But with time I came to know really it is something very valuable, that I 
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needed to be involved in.  It's actually more to support me into the better conduct of the 
studies.”    
Investigator, EACCR 6 
 
‘I could see that something was, that a monster was being created…this is the whole area of 
sort of ethics regulation and so and it seemed to be only one direction of travel which was 
more and more heavy questions and demands and requirements and the net result was 
more and more paperwork, more and more time devoted towards it.’   
Investigator, MORU 26  
 
Investigators were keen to be involved in planning monitoring activities and valued the 
input of monitors who “understand what we call the main focus of the study and give credit 
to the investigator who have long experience” (Investigator, MORU 11). They particularly 
appreciated monitors who worked with them to rectify faults and increase research 
capacity.   
 
MORU investigators described how the establishment of the CTSG has allowed them to 
exercise more control over how trials are monitored. They can draw on the expertise of 
CTSG members to ensure that monitoring activities target the greatest risks to participants 
and the most scientifically relevant data points. This has helped them develop a counter 
argument against some of the bureaucracy they believe is hampering the conduct of 
biomedical research. The EACCR reciprocal monitoring scheme was credited with 
strengthening quality management across the network, and appreciated by monitors as 
means of professional development and exchange. Across both case studies much value was 
attributed to a non-threatening ‘shared learning’ style of monitoring, which prioritized the 
resolution of problems.   
 
'…because it's a sort of cooperative monitoring and not hostile, you're much more likely to 
get problems sorted out rather than hidden.’  
Investigator, MORU 17 
 
It was evident that participants wanted monitoring to be scientifically grounded to ensure 
that quality checks are tailored to primary study outcomes. This type of monitoring requires 
monitors to work closely with investigators from the planning stages of studies.  Much 
emphasis was also placed on the need to complement checking activities with tailored 
support and training. Investigators were positive about the need for correction, especially 
when monitors worked with them to improve their work. Participants concurred that the 
purpose of monitoring should be to improve the conduct of health research and increase 
the capacity of researchers and trial sites. In other words monitoring should ‘help sites 
achieve what they are supposed to achieve’ and offer ‘assurance to investigators that they 
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are doing things the right way’.  In practice this type of monitoring replaced negative 
associations with more positive views of monitoring.  
 
 
‘Yeah when a monitor they actually come in to help you do your work better, they're not 
coming to police you or to find mistakes…they're coming to help you do your work better.’  
Monitor, EACCR 3 
 
 
The Practice of Monitoring: What constitutes professional practice? 
 
The 'who' of monitoring 
 
Participants’ experiences of monitoring suggest that the organisational ethos of monitoring 
bodies has a bearing on the practice of monitoring. It was evident from participants’ 
accounts that monitors from external bodies sometimes distanced themselves from 
research staff. In contrast EACCR monitors conveyed the notion that ‘we are doing this 
together’, similarly the positioning of the CTSG as an internal monitoring group within 
MORU enhanced interactions between researchers and monitors and increased 
transparency. On the other hand some MORU investigators felt that research staff were 
more ‘alert and ready’ during monitoring visits from external groups. 
 
These observations about interactions between monitors from different organisations and 
investigators raise important points about accountability and professional relationships. 
EACCR monitors for example argued that monitors can identify with the site whilst 
remaining accountable to the study sponsor, and MORU investigators maintained that the 
positioning of the CTSG does not pose a conflict of interest. To the contrary they work 
together more easily because their professional relationship is built on trust and mutual 
understanding. According to a study nurse this prior knowledge reduced the stress 
associated with monitoring but it did not alter the need for correction.  Internal monitors 
applied the same standards as external monitors but their proximity meant that they were 
more accessible and could provide on-going support.  
 
Yeah for me I think it's not so hard because it's not like the investigator is against the 
sponsor.  So it's not like they're trying to identify with you as opposed to the sponsor.  
They're just when they are on the site they're talking we.  We can do this…and the way I see 
it, it's not hard for them to identify with the site.  
 Monitor EACCR, 27  
 
CTSG they will know the protocol very well and they will know us quite well I have to admit 
it, but that doesn't provide conflict of interest…in a way it make us work together easier. 
Investigator MORU, 11 
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Monitors background, training and expertise and their understanding of the research 
context were viewed as important in terms of professional practice. One investigator said 
that he judged the value of monitors work by the ‘quality of the information they are able to 
detect’ (Investigator, EACCR 7).  Health professionals with experience of working in research 
were regarded as particularly well equipped to be monitors.  A role, which was also thought 
to require motivation and commitment, attention to detail, good interpersonal and 
communication skills and the ability to apply and interpret ethics guidelines in practice. With 
reference to the latter an investigator emphasised that monitors needed to understand the 
scientific purpose of the research in order to ‘think about the patient's interests and how 
they could advocate for those, or how they could check for those’ (Investigator MORU, 20).    
 
Much value was attributed to context informed monitoring and investigators resented 
monitors who did little to consider cultural norms, logistical limitations and local 
regulations.  
 
‘They come and they have such little time and they will have to do so much so they're in a 
rush and sometimes they're really distressed to try and meet their milestones.  And then the 
other thing that I have seen is inability to understand the culture and even local regulations 
sometimes, harmonising and local regulations and sponsors, SOPs and their own regulations 
back in their country, it's such a big issue.  So they come out and they would like things done 
the way they understand it.  A few times we took it upon ourselves to really train them on 
our culture, what is acceptable, what cannot be done’.   
Investigator EACCR, 10  
 
This investigator is arguing that an appreciation of local norms, customs and regulations is 
prerequisite for effective and professional monitoring practice. Local monitors were 
considered well placed to undertake context informed monitoring, and external monitors 
who demonstrated a willingness to learn rather than simply impose ideas were also highly 
valued. When it comes to the ‘who’ of monitoring what counts is mutual respect, 
communication, professionalism, and maintaining high standards irrespective of the 
positioning of the monitor in regards to the sponsor and researcher.  
 
The 'what' and 'how' of monitoring 
 
When it came to the practicalities of monitoring what counted was getting the focus and the 
approach right.  Focus requires careful planning and CTSG participants stressed the 
importance of developing monitoring plans with investigators. This planning helped them to 
identify the main risks to a study’s integrity with reference to ethics and key study 
outcomes. It helped them differentiate between minor and major errors thereby avoiding 
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diverting unwarranted time to rectifying the former.  Focus also involves achieving the right 
balance between paper work and observing research in practice.  
 
 
‘I mean sometimes documents don't, may not give, tell you, give you, the clear picture of 
how things are run.  Sometimes talking to people, asking people questions, seeing what 
people are doing can assure you, can tell you a number of things that you can't see by 
looking at the documents.’ 
Key Informant EACCR, 28 
 
Concerns were raised by investigators about the amount of time monitors (coming from 
long distances) end up spending sitting in rooms verifying files and source documents. It was 
argued that on-site monitoring should not be confined to document review but include 
observational and interactive activities, which allow monitors to gain greater insights into 
how a trial is being implemented and where corrective action is needed.  
 
Two distinct ways of organising monitoring activities were described. One where the 
monitor performs their review presents findings in debriefing meetings, and sends a 
summary report with action points; and the other where the monitor actively engages 
research staff in resolving issues during the on-site visit. The components of monitoring 
visits were similar but the engagement differed.  Investigators expressed preference for the 
latter but also noted that this method was time-consuming and impractical when the 
research clinics are busy.  
 
A monitor’s personal and professional approach was viewed as crucial to promoting positive 
interactions and improving the quality of trials.  
 
 ‘The key thing about successful monitoring is how you present, how the monitor presents 
themselves and involves themselves with the investigators’  
Investigator MORU, 26 
 
Monitors need to gain the trust of investigators and interviewees argued that the best way 
to do this is to work with investigators to improve study conduct. It was evident that 
investigators were anxious about discussing problems or disclosing important information to 
overly critical monitors. One investigator (Investigator EACCR, 7) described how his team’s 
‘fear just melted away’ when they realised that their monitor’s approach (an external CRO 
monitor) was not adversarial ‘you did this wrong, we are going to beat you’, but constructive 
‘he’s like trying to make you improve’.  
 
The core features of a professional approach to monitoring were cited as a commitment to 
high standards, open communication and positive interactions, mutual respect and a 
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friendly manner.  Investigators appreciated monitors who maintained high standards in a 
strict and firm manner and worked with them to enhance the quality of their work.  
 
 
DISCUSSION 
 
Our participatory evaluation provides important insights about the practice of international 
on-site monitoring, and the value of utilizing internal and network expertise to enhance trial 
quality. Particular emphasis was given to a cooperative style of monitoring as a means of 
enhancing trust and transparency. Whilst this style of monitoring was associated with the 
EACCR and MORU models, it is important to note that some participants commented 
positively on interactions with CRO monitors. With reference to practice our findings 
suggest that the primary purpose of on-site monitoring is to improve the conduct of health 
research and increase the capacity of researchers and trial sites. Monitoring activities to be 
scientifically grounded, contextually and culturally informed with tailored support and 
training. Skills in the scientific evaluation of trials and a willingness to work closely with 
investigators were viewed as critical for the development of effective risked-based and 
context informed monitoring plans. It was argued that on-site monitoring should combine 
document verification with observational activities, and be complemented by training and 
mentoring to enable investigators to execute necessary corrective actions. Indeed our data 
suggest that the success of monitoring should be measured by corrective action rather than 
by identification of faults. Monitoring reports should only include findings, which could 
significantly impact on the scientific and ethical integrity of the trials.  
 
The main benefits of the MORU and EACCR monitoring models are: 1) Reduced logistical 
costs, 2) Increased site capacity for quality management, 3) Investigators contribution to 
risk-based monitoring plans, 4) Professional development and exchange. The latter is of 
relevance given the increased value attributed in the health sector to ‘Communities of 
Practice’ as a means of encouraging situated learning and the practical application of 
knowledge[23].  Communities of practice are defined as: ‘groups of people who share a 
concern, a set of problems, or a passion about a topic, and who deepen their knowledge and 
expertise in this area by interacting on an on-going basis’[24]. The challenges relate to 
questions of sustainability and credibility. There is a need to consider the logistics and 
funding of these models to ensure that their benefits are sustainable. Currently both models 
rely heavily on grants rather than charging trials directly for their services. This needs to be 
remedied in order to reduce dependency on external funding.  
 
The strengths of this empirical study are that it contributes to the literature documenting 
good practice at international trial sites in resource-constrained settings. As noted in the 
background section Macefield et al [20] were only able to include 7 multinational trials in 
their systematic review. Given the study design one inherent limitation is the paucity of 
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quantitative findings.  Follow up studies will need to systematically collate information on 
trial costs, and provide monitoring report templates.  An additional weakness of our work is 
that we were not able to compare the monitoring reports of studies monitored by MORU 
and EACCR RMS, and other sponsor delegated monitoring groups. A key area for future 
research will be to conduct a mixed methods study, which evaluates how the EACCR and 
MORU on-site monitoring models work in combination with CSM.  
 
 
CONCLUSIONS 
 
Innovative monitoring models, which prioritise the sensible application of regulations and 
ethical guidelines are imperative to facilitate vital global health research.  The experience 
gained in developing the innovative international models studied in this paper offers 
valuable insights. Both models utilize internal and network wide expertise to improve the 
ethics and quality of clinical research. They demonstrate how monitoring can be a 
constructive exercise rather than threatening process. The value of cooperative relations 
needs more emphasis in this field given that sponsors, investigators and monitors are jointly 
responsible for ensuring that research protects human rights and produces reliable data, 
which can improve human health. 
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